| PH |
Report |
Adjusted EPS (Q4 FY26) |
BEAT |
pred ~$8.40 vs. cons $8.30 |
MEDIUM |
| PH |
Report |
Revenue (Q4 FY26) |
BEAT |
pred ~$5.68B vs. cons $5.61B |
MEDIUM |
| PH |
Report |
Aerospace organic growth (Q4 FY26) |
BEAT |
pred ~11% vs. cons/guide ~9% |
HIGH |
| PH |
Guide |
FY27 reported sales growth (initial guide) |
BETTER |
guide ~9% vs. cons ~6% (FY27) |
MEDIUM |
| PH |
Guide |
FY27 adjusted EPS (initial guide) |
BETTER |
guide ~$33.50 vs. cons $32.50 (FY27) |
MEDIUM |
| PH |
Guide |
Aerospace organic growth outlook (FY27) |
BETTER |
guide ~7% vs. cons ~6% (FY27) |
MEDIUM |
| PH |
Guide |
Industrial organic growth outlook (FY27) |
BETTER |
guide ~3% vs. cons ~2.5% (FY27) |
LOW |
| PH |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| PH |
Return |
5-day cumulative residual |
-3.0% (FADE) |
PH enters the print at record highs (~$997) and a stretched multiple (~29x F27E EPS, 21.3x EBITDA) with Street estimates ($8.30/$5.61B) already running ABOVE management's own conservative Q4 guide ($8.16/$5.5B) — the opposite setup from Q3, when a beat-and-raise still triggered a 5.46% pre-market decline on valuation grounds. Even with another likely Q4 beat and a directionally 'better' initial FY27 framework (boosted by Filtration Group/CIRCOR Aerospace inorganic contribution), the initial FY27 EPS guide will likely embed conservative assumptions plus new interest expense/dilution from the $7.75B delayed-draw facilities funding Filtration Group, prompting sell-side to trim near-term (FY27 H1) numbers even as headline growth rates look strong — an implicit-cut dynamic that fades an initial pop or deepens an initial dip over the following days as analysts rework models around deal financing and integration costs. |
MEDIUM |